Aldeyra Therapeutics Inc. is making another run at U.S. FDA clearance for reproxalap in dry eye disease (DED) after nailing ...

Aktiia SA raised $42 million in an oversubscribed series B funding round and rebranded to Hilo. The funds will be used for product innovation, expansion into new markets and to build out its blood ...

Innovent Biologics Inc.’s efdamrofusp alfa (IBI-302) met the primary endpoint in phase II, showing a gain of 10 or more letters in visual acuity from baseline at one year in Chinese patients with ...

Actuate Therapeutics Inc. said its lead candidate, elraglusib, in pancreatic cancer demonstrated a substantial improvement in median overall survival compared to data from the same phase II study ...

Q’apel Medical Inc., of Fremont, Calif., might have thought the company’s withdrawal of the Hippo catheter was nothing but a loss, but Route 92 Medical Inc. managed to shine a positive light on the ...

The U.K. National Institute for Health and Care Excellence (NICE) opened a late-stage assessment for drug-eluting stents (DES) with an eye toward costs, advising clinicians that they should implant ...

Protein phosphatase 2A (PP2A) is a key serine/threonine phosphatase that controls various signaling pathways and influences cancer development and treatment outcomes.

Aiming to develop a systemic therapy for advanced refractory cancers, researchers have designed a novel oncolytic adenovirus that selectively targets and kills cancer cells expressing mesothelin.

Cellecta Inc. made remote diagnostics and decentralized clinical trials significantly easier with the launch of its Drivermap Exp assay. The microsampling kit provides a “molecular snapshot” of 19,000 ...

U.S. FDA Commissioner Marty Makary is starting to fill the vacancies at the agency that’s seen its senior leadership ravaged by retirements and terminations. Makary’s first pick is Vinay Prasad as the ...

PARP inhibitors have been approved for the treatment of several cancers, including ovarian, breast, pancreatic and prostate cancers with BRCA mutations or other homologous recombination repair ...

Prostate cancer remains a significant health concern for men globally, and the search for effective and targeted therapies continues. In a recent study, researchers from Guizhou Medical University ...